ASCO 2023
Jun 2 - 6, 2023 | Chicago, IL
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
TACTIVE-U: Phase 1b/2 Umbrella Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Combined with Other Anticancer Treatments in ER+ Advanced or Metastatic Breast CancerRM Layman et al.
Poster
VERITAC-2: A Global, Randomized Phase 3 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast CancerM Campone et al.